CLINICAL TRIALS NETWORK MID-ATLANTIC COLLABORATIVE GROUP

这是一项建立计划中的NIDA国家药物滥用治疗临床试验网络的中大西洋区域节点的建议。这个中大西洋地区包括马里兰州、弗吉尼亚州和华盛顿特区，并涉及该地区主要大学（约翰霍普金斯大学医学院、弗吉尼亚联邦大学、马里兰大学）和各种社区药物滥用治疗项目之间的合作努力。这些社区治疗项目为大量具有人口统计学、诊断和症状多样性的药物滥用患者提供了临床研究途径，也为治疗项目提供了在治疗服务提供的类型、方式和重点方面具有巨大多样性的治疗项目。这些学术和社区治疗项目已经建立了强有力的合作关系，并共同致力于系统的社区研究，这些研究将直接评估社区治疗项目中不同药物滥用治疗和服务的有效性，并将评估和研究与采用改进治疗有关的因素，这是RFA所要求的。学术中心在开展和管理药物滥用治疗的对照临床试验方面拥有丰富的经验和专业知识，包括行为治疗和药理学治疗，以及针对各种不同类型的物质使用障碍（海洛因、可卡因、镇静剂、酒精、烟草）的综合行为-药理学治疗。这些中心在社区治疗项目的培训、实施和评估方面也有丰富的经验和专业知识。本合作小组拟加入NIDA临床试验网络，在社区诊所开展药物滥用行为和/或药理治疗的对照试验，研究新疗法在社区诊所采用的过程及其影响。

This is a proposal to create a Mid-Atlantic regional node of the planned NIDA National Drug Abuse Treatment Clinical Trials Network. This Mid-Atlantic region incorporates Maryland, Virginia, and Washington, D.C., and involves a collaborative effort among major universities in the region (Johns Hopkins University School of Medicine, Virginia Commonwealth University, University of Maryland) and a diverse array of community drug abuse treatment programs. These community treatment programs provide clinical research access to a large population of drug abuse patients with great demographic, diagnostic, and syndromal diversity, as well as to treatment programs representing great diversity in the types, modalities, and focus of their treatment service delivery. These academic and community treatment programs have established strong collaborative relations and are jointly committed to systematic community-based research that will assess the effectiveness of different drug abuse treatments and services directly in community treatment programs, and that will assess and study factors related to adoption of improved treatments, as requested in the RFA. The academic centers have extensive experience and expertise in conducting and managing controlled clinical trials of drug abuse treatments, including both behavioral treatments and pharmacological treatments, as well as integrated behavioral-pharmacological treatments, for a broad range of different types of substance use disorders (heroin, cocaine, sedatives, alcohol, tobacco). The centers also have extenisve experience and expertise in training, implementation, and assessment within community treatment programs. This collaborative group proposes to participate in the NIDA Clinical Trials Network, to conduct controlled trials of behavioral and/or pharmacological drug abuse treatments in community clinics, and to investigate the process of and influences on community clinic adoption of new treatments.